These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 12421641

  • 1. Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia.
    Richter A, Löscher W.
    Eur J Pharmacol; 2002 Nov 15; 454(2-3):145-51. PubMed ID: 12421641
    [Abstract] [Full Text] [Related]

  • 2. (+)-WIN 55,212-2, a novel cannabinoid receptor agonist, exerts antidystonic effects in mutant dystonic hamsters.
    Richter A, Löscher W.
    Eur J Pharmacol; 1994 Nov 03; 264(3):371-7. PubMed ID: 7698178
    [Abstract] [Full Text] [Related]

  • 3. Cannabinoid modulation of intestinal propulsion in mice.
    Colombo G, Agabio R, Lobina C, Reali R, Gessa GL.
    Eur J Pharmacol; 1998 Feb 26; 344(1):67-9. PubMed ID: 9570450
    [Abstract] [Full Text] [Related]

  • 4. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
    McMahon LR, Koek W.
    Eur J Pharmacol; 2007 Aug 13; 569(1-2):70-6. PubMed ID: 17553486
    [Abstract] [Full Text] [Related]

  • 5. R+-methanandamide inhibits tracheal response to endogenously released acetylcholine via capsazepine-sensitive receptors.
    Nieri P, Martinotti E, Testai L, Adinolfi B, Calderone V, Breschi MC.
    Eur J Pharmacol; 2003 Jan 10; 459(1):75-81. PubMed ID: 12505536
    [Abstract] [Full Text] [Related]

  • 6. The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2.
    Darmani NA.
    Eur J Pharmacol; 2001 Oct 26; 430(1):49-58. PubMed ID: 11698062
    [Abstract] [Full Text] [Related]

  • 7. SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity.
    Pan X, Ikeda SR, Lewis DL.
    Mol Pharmacol; 1998 Dec 26; 54(6):1064-72. PubMed ID: 9855635
    [Abstract] [Full Text] [Related]

  • 8. Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR 141716A.
    Vivian JA, Kishioka S, Butelman ER, Broadbear J, Lee KO, Woods JH.
    J Pharmacol Exp Ther; 1998 Aug 26; 286(2):697-703. PubMed ID: 9694923
    [Abstract] [Full Text] [Related]

  • 9. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats.
    Izzo AA, Mascolo N, Pinto L, Capasso R, Capasso F.
    Eur J Pharmacol; 1999 Nov 12; 384(1):37-42. PubMed ID: 10611417
    [Abstract] [Full Text] [Related]

  • 10. CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55212-2 [(4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1ij]quinolin-6-one]-induced hypothermia.
    Rawls SM, Cabassa J, Geller EB, Adler MW.
    J Pharmacol Exp Ther; 2002 Jun 12; 301(3):963-8. PubMed ID: 12023525
    [Abstract] [Full Text] [Related]

  • 11. Effects of cannabinoid receptor agonists on neuronally-evoked contractions of urinary bladder tissues isolated from rat, mouse, pig, dog, monkey and human.
    Martin RS, Luong LA, Welsh NJ, Eglen RM, Martin GR, MacLennan SJ.
    Br J Pharmacol; 2000 Apr 12; 129(8):1707-15. PubMed ID: 10780977
    [Abstract] [Full Text] [Related]

  • 12. Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB(1) receptors.
    Landi M, Croci T, Rinaldi-Carmona M, Maffrand JP, Le Fur G, Manara L.
    Eur J Pharmacol; 2002 Aug 16; 450(1):77-83. PubMed ID: 12176112
    [Abstract] [Full Text] [Related]

  • 13. Cannabinoid CB(2) receptor activation prevents bronchoconstriction and airway oedema in a model of gastro-oesophageal reflux.
    Cui YY, D'Agostino B, Risse PA, Marrocco G, Naline E, Zhang Y, Chen HZ, Finance O, Rinaldi-Carmona M, Rossi F, Advenier C.
    Eur J Pharmacol; 2007 Nov 14; 573(1-3):206-13. PubMed ID: 17643417
    [Abstract] [Full Text] [Related]

  • 14. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.
    Darmani NA.
    Neuropsychopharmacology; 2001 Feb 14; 24(2):198-203. PubMed ID: 11120402
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
    McMahon LR.
    J Pharmacol Exp Ther; 2006 Dec 14; 319(3):1211-8. PubMed ID: 16943255
    [Abstract] [Full Text] [Related]

  • 18. Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects.
    Wallace MJ, Wiley JL, Martin BR, DeLorenzo RJ.
    Eur J Pharmacol; 2001 Sep 28; 428(1):51-7. PubMed ID: 11779037
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice.
    Smith SR, Terminelli C, Denhardt G.
    J Pharmacol Exp Ther; 2000 Apr 28; 293(1):136-50. PubMed ID: 10734163
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.